Results 61 to 70 of about 23,609 (230)
Idiopathic splanchnic vein thrombosis: is it really idiopathic?
Haematologica, 2022 Giovanni Barosi
doaj +1 more source
CLINICAL AND PATHOMORPHOLOGICAL EXAMINATION OF MYELOFIBROSIS IN CHRONIC MYELOID LEUKEMIA
Сибирский онкологический журнал, 2016 Pathomorphology study of marrow fibrosis in patients with chronic myeloid leukemia was carried out using morphometric image analysis software. It was revealed that every second patient had myelofibrosis.
T. Yu. Dolgikh +3 more
doaj
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background For patients with locally advanced (la) or metastatic (m) cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery/radiation or systemic anti‐PD1 therapy, anti‐EGFR in combination with chemotherapy is a rational treatment option.
Julia Huynh +5 more
wiley +1 more source
European Journal of Haematology, EarlyView.ABSTRACT JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers.
Steffen Koschmieder +15 more
wiley +1 more source
Single-cell analysis based dissection of clonality in myelofibrosis
Nature Communications, 2020 Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas +21 more
doaj +1 more source
Contraception in Myeloproliferative Neoplasms: A Pharmacological Review
European Journal of Haematology, EarlyView.ABSTRACT Myeloproliferative neoplasms (MPNs) are chronic hematologic disorders characterized by clonal proliferation of myeloid lineage cells, commonly driven by JAK2 mutations, and associated with significant thrombotic and hemorrhagic complications.
Awni Alshurafa +4 more
wiley +1 more source
Primary autoimmune myelofibrosis: a report of three cases and review of the literature
Turkish Journal of Hematology, 2009 Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE).
Rakhee Kar, Shyamali Dutta, Seema Tyagi
doaj
Онкогематология, 2016 Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxicity ...
M. S. Fominykh +5 more
doaj +1 more source
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction The majority of patients with essential thrombocythemia (ET) show somatic mutations of JAK2, CALR, or MPL. Around 10% of cases lack these mutations (“triple negative” ET, TN‐ET). Additionally, some patients with bona fide “primary thrombocytosis” (PT) [i.e., high platelet (PLT)‐ count with no apparent underlying causes] do not ...
Valentina Sangiorgio +8 more
wiley +1 more source